Emily Schultz

5PUBLICATIONS
7CO-AUTHORS
Cancer geneticsMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Apr 16, 2026
Increasing Use of Germline Genetic Testing in Pancreatic Ductal Adenocarcinoma and Relationship to Clinical Outcome: A Single-Institution Study.

|Jan 23, 2026
Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors.

Thomas N O'Connor, Emily Schultz, Sheheryar Kabraji

|Feb 26, 2025
Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer.

Agnieszka K Witkiewicz, Jianxin Wang, Emily Schultz

|May 11, 2024
Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy.

Thomas N O'Connor, Emily Schultz, Jianxin Wang

|Sep 13, 2023
Determinants of response to CDK4/6 inhibitors in the real-world setting.

Agnieszka K Witkiewicz, Emily Schultz, Jianxin Wang

Pageof 1

Frequent Collaborators

4 joint publications

Erik S Knudsen

3 joint publications

Thomas N O'Connor

2 joint publications

Ellis Levine

1 joint publications

Jianxin Wang